Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer

Surgery Today

Volumn 38, Issue 11, 2008, Pages 1013-1020

  Emi, Yasunori ^a   Yamamoto, Manabu ^b   Takahashi, Ikuo ^c   Orita, Hiroyuki ^d   Kakeji, Yoshihiro ^a   Kohnoe, Shunji ^e   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^c MATSUYAMA RED CROSS HOSPITAL   (Japan)

^d Saiseikai Yahata Hospital   (Japan)

^e FUKUOKA DENTAL COLLEGE   (Japan)

Author keywords

Advanced gastric cancer; Dose dense therapy; Paclitaxel; Phase II trial

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PERFORMANCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PREMEDICATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; STOMACH NEOPLASMS;

EID: 55249096993     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-008-3769-8     Document Type: Article

References (44)

1. Cancer Statistics in Japan 2007. In: The Editorial Board of the Cancer Statistics in Japan, editors. Foundation for Promotion of Cancer Research (FPCR); 2007. p. 12-38.
2. E.V. Cutsem D. Haller A. Ohtsu 2002 The role of chemotherapy in the current treatment of gastric cancer Gastric Cancer 5 suppl1 17 22
3. S. Pyrhönen T. Kuitunen P. Nyandoto M. Kouri 1995 Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587 591
4. A.M. Murad F.F. Santiago A. Petroianu P.R.S. Rocha M.A.G. Rodrigues M. Rausch 1993 Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37 41
5. B. Glimelius K. Hoffman U. Haglund O. Nyrén P.O. Sjödén 1994 Initial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 189 190
6. A. Ohtsu Y. Shimada K. Shirao N. Boku I. Hyodo H. Saito 2003 Japan Clinical Oncology Group Study (JCOG9205). Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer J Clin Oncol 21 54 59
7. J.S. Waters A. Norman D. Cunningham J.H. Scarffe A. Webb P. Harper 1999 Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial Br J Cancer 80 269 272
8. U. Vanhoefer P. Rougier H. Wilke M.P. Ducreux A.J. Lacave E. Van Cutsem 2000 Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 18 2648 2657
9. P. Ross M. Nicolson D. Cunningham J. Valle M. Seymour P. Harper 2002 Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer J Clin Oncol 20 1996 2004
10. E. Van Cutsem V.M. Moiseyenko S. Tjulandin A. Majlis M. Constenla C. Boni 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991 4997
11. N. Boku S. Yamamoto K. Shirao T. Doi A. Sawaki W. Koizumi 2007 Gastrointestinal Oncology Study Group/Japan Clinical Oncology Group. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912) J Clin Oncol 25 suppl LBA4513
12. H. Narahara W. Koizumi T. Hara A. Takagane T. Akiya M. Takagi 2007 TS-1 Advanced Gastric Cancer (AGC) Clinical Trial Group. Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer J Clin Oncol 25 suppl 4514
13. K. Sugimachi Y. Maehara 2000 A phase II trial of a new 5-fluorouracil derivative, BOF-A2 (Emitefur), for patients with advanced gastric cancer Surg Today 30 1067 1072
14. M.C. Wani H.L. Taylor M.E. Wall P. Coggon A.T. McPhail 1971 Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia J Am Chem Soc 93 2325 2327
15. P.B. Schiff J. Fant S.B. Horwitz 1979 Promotion of microtubule assembly in vitro by taxol Nature 277 665 667
16. E.K. Rowinsky L.A. Cazenave R.C. Donehower 1990 Taxol: a novel investigational antimicrotubule agent J Natl Cancer Inst 82 1247 1259
17. F.A. Holmes R.S. Walters R.L. Theriault A.D. Forman L.K. Newton M.N. Raber 1991 Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer J Natl Cancer Inst 83 1797 1805
18. A.I. Einzig P.H. Wiernik J. Sasloff C.D. Runowicz G.L. Goldberg 1992 Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma J Clin Oncol 10 1748 1753
19. A.I. Einzig H. Hochster P.H. Wiernik D.L. Trump J.P. Dutcher E. Garowski 1991 A phase II study of taxol in patients with malignant melanoma Invest New Drugs 9 59 64
20. A.Y. Chang K. Kim J. Glick T. Anderson D. Karp D. Johnson 1993 Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results J Natl Cancer Inst 85 388 394
21. Y. Yamada K. Shirao A. Ohtsu N. Boku I. Hyodo H. Saitoh 2001 Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions Ann Oncol 12 1133 1137
22. E.A. Eisenhauer W.W. ten Bokkel Huinink K.D. Swenerton L. Gianni J. Myles M.E. van der Burg 1994 European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion J Clin Oncol 12 2654 2666
23. Y. Kodera S. Ito Y. Mochizuki S. Fujitake K. Koshikawa Y. Kanyama 2007 A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study) Anticancer Res 27 2667 2671
24. P. Therasse S.G. Arbuck E.A. Eisenhauer J. Wanders R.S. Kaplan L. Rubinstein 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216
25. Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. Part IV. Response assessment of chemotherapy for gastric carcinoma. 1st English ed. Tokyo: Kanehara; 1995. p. 90-104.
26. J.A. Ajani J. Fairweather P. Dumas Y.Z. Patt R. Pazdur P.F. Mansfield 1998 Phase II study of Taxol in patients with advanced gastric carcinoma Cancer J Sci Am 4 269 274
27. S. Cascinu F. Graziano N. Cardarelli M. Marcellini P. Giordani E.T. Menichetti 1998 Phase II study of paclitaxel in pretreated advanced gastric cancer Anticancer Drugs 9 307 310
28. A.A. Garcia C.G. Leichman H.J. Lenz J. Baranda R. Lujan Y. Casagrande 2001 Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach Jpn J Clin Oncol 31 275 278
29. K. Yamaguchi M. Tada N. Horikoshi T. Otani H. Takiuchi S. Saitoh 2002 Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer Gastric Cancer 5 90 95
30. A.D. Seidman C.A. Hudis J. Albanell W. Tong I. Tepler V. Currie 1998 Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer J Clin Oncol 16 3353 3361
31. M. Kimura T. Koida Y. Yanagita 2000 Weekly administration of paclitaxel for advanced or metastatic breast cancer-short-course premedication for outpatients (in Japanese with English abstract) Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 27 1703 1708
32. P. Fidias J.G. Supko R. Martins A. Boral R. Carey M. Grossbard 2001 A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer Clin Cancer Res 12 3942 3949
33. M. Markman J. Hall D. Spitz S. Weiner L. Carson L. Van Le 2002 Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer J Clin Oncol 20 9 2365 2369
34. R. Kim A. Osaki T. Toge 2001 Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancer Oncol Rep 8 1171 1176
35. P. Rosenberg H. Andersson K. Boman M. Ridderheim B. Sorbe U. Puistola 2002 Randomized trial of single agent paclitaxel given weekly versus every three weeks and with per oral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum Acta Oncol 41 418 424
36. M.C. Green A.U. Buzdar T. Smith N.K. Ibrahim V. Valero M.F. Rosales 2005 Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks J Clin Oncol 23 5983 5992
37. M. Tahara A. Ohtsu N. Boku F. Nagashima M. Muto Y. Sano 2001 Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study Gastric Cancer 4 212 218
38. J. Sakamoto S. Morita T. Yumiba H. Narahara K. Kinoshita Y. Nakane 2003 A phase II clinical trial to evaluate the effect of paclitaxel in patients with ascites caused by advanced or recurrent gastric carcinoma: a new concept of clinical benefit response for non-measurable type of gastric cancer Jpn J Clin Oncol 33 238 240
39. A. Hagiwara T. Takahashi O. Kojima K. Sawai T. Yamaguchi T. Yamane 1992 Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer Lancet 339 8794 629 631
40. W. Adachi S. Koike M. Rafique S. Kajikawa G. Kaneko T. Kuroda 1995 Preoerative intraperitoneal chemotherapy for gastric cancer, with special reference to delayed peritoneal complications Surg Today 25 396 403
41. K.P. O'Boyle Y. Wang E.L. Schwartz D.L. Regl A. Einzig J.P. Dutcher 1997 Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids Cancer 79 1022 1030
42. M. Kobayashi J. Sakamoto T. Namikawa K. Okamoto T. Okabayashi K. Ichikawa 2006 Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients World J Gastroenterol 12 1412 1415
43. T. Ishida H. Shimokawa K. Kawaguchi N. Nose T. Ikegami H. Itoh 2002 Effective weekly paclitaxel administration for gastric cancer with malignant ascites - a case report (in Japanese with English abstract) Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 29 1643 1646
44. M. Kobayashi K. Oba J. Sakamoto K. Kondo N. Nagata T. Okabayashi 2007 Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan Gastric Cancer 10 52 57